Type 2 diabetes: Added benefit of linagliptin is not proven, study suggests

Linagliptin is approved to improve blood glucose control in adults with type 2 diabetes mellitus. As the drug manufacturer chose a different appropriate comparator therapy than specified by the Federal Joint Committee, no proof of an added benefit of linagliptin can be inferred from the manufacturer's dossier.

Read the whole article on Science Daily

More from Science Daily